Nordihydroguaiaretic acid (NDGA) is a major biologically active component of the creosote bush, Larrea tridentate, widely used in unregulated therapies. NDGA is a lipoxygenase inhibitor while a derivative, terameprocol, has been trialed as a chemotherapeutic agent. When investigating fatty acid activation of the human transient receptor potential cation channel subfamily A, member 1 (hTRPA1), we found that NDGA activated the channel. Here we investigate the actions of NDGA and terameprocol at hTRPA1 and the consequences of this for noxious cold sensitivity in mice. hTRPA1 was stably expressed in HEK 293 cells (HEK 293-TRPA1) and channel activity examined by measuring changes in intracellular calcium ([Ca] i ) using a fluorescent dye and activation of membrane currents using patch clamp electrophysiology. The effects of local NDGA and terameprocol application on acetone-induced paw flinching were examined in mice. NDGA (pEC 50 of 5.4 AE 0.1, maximum change in fluorescence of 385 AE 30%) and terameprocol (pEC 50 4.5 AE 0.2, maximum 550 AE 75%) increased [Ca] i in HEK 293-hTRPA1 cells. NDGA also induced an increase in membrane conductance in HEK 293-hTRPA1 cells. These effects were prevented by the TRPA1 antagonist HC-030031, and were dependent on the presence of Cys621, Cys 641, and Cys 665 in hTRPA1. Neither NDGA nor terameprocol alone produced spontaneous pain behaviors in mice after hind paw injection, but both enhanced responses to acetone. NDGA and terameprocol are efficacious activators of TRPA1. NDGA should be used with care to probe lipoxygenase involvement in nociception while TRPA1 activity should be considered when considering use of these drugs in humans.
Introduction
Nordihydroguaiaretic acid (NDGA) is a major pharmacologically active component of the creosote bush (Larrea tridentata). Creosote extracts ("Chaparral tea") have been traditionally used to treat a wide variety of conditions (Arteaga et al. 2005) , and continue to be advertised extensively in unregulated environments, despite well recognized toxicity (Sheikh et al. 1997 ) and the banning of NDGA from food in the United States more than 40 years ago (http://www.accessdata.fda.gov). NDGA and related molecules inhibit lipoxygenases in addition to a variety of other enzymes, and are also antioxidants (Lu et al. 2010) . These properties may contribute to antiinflammatory properties attributed to crude preparations. Synthetic derivatives of NDGA, including tetra-o-methyl NDGA (terameprocol, formerly M 4 N or EM-1421) inhibit the activity of the transcription factor Sp1, leading to inhibition of viral replication and tumor cell growth (Chen et al. 1998; Hwu et al. 1998; Chang et al. 2004; Castro-Gamero et al. 2013) .
NDGA has been widely used in experimental studies of inflammation (e.g., Yoo et al. 2009; Xue et al. 2013 ) and its main mechanism of action appears to be through its unspecific inhibition of lipoxygenase (Salari et al. 1984; Gregus et al. 2013) and by acting as a scavenger of reactive oxygen species (ROS, Floriano-Sanchez et al. 2006; Lu et al. 2010) . NDGA may also suppress tumor growth in part via its lipoxygenase inhibition and antioxidant properties (Kubow et al. 2000) .
While investigating the activation of the pronociceptive ion channel transient receptor potential cation channel subfamily A (TRPA1) (Jordt et al. 2004 ) by arachidonic acid and potential metabolites (Redmond et al. 2014 ), we used NDGA as a lipoxygenase inhibitor and unexpectedly found that NDGA itself activated human TRPA1 with a potency similar to that of the widely used agonist cinnamaldehyde (CA). The discovery of TRPA1 agonist activity for NDGA and its derivative terameprocol may not only provide insight into their potential therapeutic mechanism(s) of action, but also suggest that care should be taken when attributing their biological effects as being solely mediated through enzyme inhibition, antioxidant activity or modulation of gene transcription.
Materials and Methods

Cell culture
Flp-In TRex HEK 293 (Life Technologies, Mulgrave, Victoria, Australia) stably transfected with wild-type or mutant hTRPA1 (Redmond et al. 2014) were cultivated in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U penicillin and 100 lg streptomycin mL À1 , hygromycin B 25 lg mL À1 and blasticidin S 5 lg mL À1 . Cells were incubated in 5% CO 2 at 37°C in a humidified atmosphere. Cells were grown in flasks with a surface area of 75 mm 2 , once at optimum confluence (approximately 90%), cells were trypsinized and transferred into clear-bottomed poly-D-lysine coated 96-well plates (Corning, Castle Hill, NSW, Australia) in L15 medium supplemented with 1% fetal bovine serum, hygromycin B, and the antibiotics outlined above. The cells were plated in a volume of 100 lL and were incubated in humidified room air at 37°C overnight. Expression of the TRPA1 receptor or mutants was induced 5-8 h prior to experimentation by addition of tetracycline, 1 lg mL À1 to each well. 0.4, glucose 10 (pH to 7.3, osmolarity = 330 AE 5 mosmol) was loaded into each well of the plate and incubated in room temperature for 1 h at 37°C. All experiments in the Flexstation were carried out at 37°C. Calcium 5 fluorescence was measured every 2 sec (k excitation = 485 nm, k emission = 525 nm) for the duration of the experiment. Drugs were added after at least 2 min of baseline recording. In experiments where one drug addition, 50 lL of drug dissolved in HBSS was added, for two drug additions, 25 lL was added each time.
Calcium assay
Electrophysiology
TRPA1 channel currents were recorded in the whole-cell configuration of the patch clamp method (Hamill et al. 1981) Animals were allowed to acclimatize to their holding cages and the behavioral testing chambers for 2-3 days before any procedures were carried out. All testing was carried out in low level white light (<3 lux). To assess cold sensitivity, the mice were allowed to acclimatize for 20-30 min prior to testing in elevated perspex cages (15 9 10 9 10 cm) with a wire mesh floor, and 20 lL of acetone was sprayed onto the plantar surface of the left hind paw to induce evaporative cooling (Gentry et al. 2010) . The number of left hind limb lifts, shakes, and licks was then counted over a 2-min period. Solutions of drugs for intraplantar injection were made up in a vehicle solution which comprised 25% dimethylsulfoxide (DMSO) and 10% Tween 80 in saline. Intraplantar injections were made in a volume of 15 lL, under brief isoflurane anesthesia (2.5% in saturated O 2 , 1 mL min À1 ) using a 30-gauge needle. Solutions of drugs for systemic injection were made up in a vehicle solution (15% DMSO in saline) and were injected intraperitoneally at a volume of 0.12 mL/10 g in lightly restrained animals.
In experiments investigating the effect of TRPA1 agonists the protocol was three predrug behavioral measurements (at 0, 15, 30 min), intraplantar agonist or vehicle injection (at 45 min), then five behavioral measurements (60, 75, 105, 135, and 165 min = 15, 30, 60, 90 , and 120 min postagonist). In experiments on the effect of HC 030031 on the TRPA1 agonists the protocol was three predrug behavioral measurements (at 0, 15, 30 min), systemic injection of HC 030031 (at 45 min), two behavioral measurements (at 60, 75 min), intraplantar agonist or vehicle injection (at 90 min), three behavioral measurements (at 105, 120, and 165 min = 15, 30, 60, 90, and 120 min postagonist). Animals were euthanized at the end of the testing period. The experimenter was blinded to the agents being tested.
For the time course experiments, comparisons of drug/ vehicle treatment effects over time were made using twoway repeated measures analyses of variance (ANOVAs), with time and treatment as a within-and between-subjects factors (GraphPad Prism). When two-way ANOVAs were significant, post hoc comparisons between treatment groups at individual time points were made using the Sidak adjustment for multiple comparisons. To measure net drug effects, the postdrug measures for acetoneinduced lifts/shakes/flicks were taken as the average of measurements over 15-60 min postdrug injection and compared to the preinjection baseline values (subtracted to give the change relative to baseline). Dose-response curves were constructed by fitting data to a four-parameter logistic Hill equation (GraphPad Prism). Statistical comparisons of the effect of CA and NDGA in the presence and absence of antagonists were made using twoway ANOVAs and when significant, post hoc comparisons were made using the Bonferroni adjustment for multiple comparisons.
Drugs and reagents
Drugs for in vitro experiments were dissolved in ethanol and diluted in HBS with a maximum final concentration of ethanol of 0.1%. NDGA, terameprocol, and HC 030031 were purchased from Cayman Chemical (Ann Arbor, MI). Ruthenium red was from Enzo Lifesciences (Farmingdale, NY). Ionomycin was from Ascent Scientific (Avonmouth, UK). CA was purchased from SigmaAldrich (Castle Hill, NSW, Australia). All tissue culture reagents were from Sigma-Aldrich, Life Technologies (Mulgrave, Victoria, Australia) or InvivoGen (San Diego, CA).
Results
NDGA produced a robust elevation of [Ca] i in HEK-293 cells expressing hTRPA1, but only a small change in HEK-293-TRPA1 cells where TRPA1 expression had not been induced by tetracycline (Fig. 1) ) produced a smaller change in fluorescence than a high concentration of CA (300 lmol L À1 , 385 AE 30% vs. 520 AE 25%, P < 0.01, n = 5).
To confirm that NDGA was activating a membrane conductance, whole-cell voltage clamp recordings were made from hTRPA1 expressing HEK 293 cells induced overnight with a low concentration of tetracycline (1 lg mL À1 ). Whole-cell currents were elicited from a holding potential of 0 mV by repeatedly ramping the membrane potential of the cells from À80 to +80 mV over 500 msec, once every 5 sec (Redmond et al. 2014) . NDGA (10 lmol L À1 ) produced a rapid increase in membrane current measured at +80 mV (from a baseline of 150 AE 8 pA to a peak of 2.2 AE 0.1 nA, n = 6, Fig. 3 ) that was strongly attenuated by coincubation of the cells with the TRPA1 antagonist HC 030031 (30 lmol L À1 ; control 94 AE 3 pA; after 2 min in HC 030031 110 AE 3 pA; after 3 min in HC 030031 and NDGA, 132 AE 2 pA n = 6, Fig. 3 ). CA and other reactive electrophiles require Cys residues in the intracellular N-terminal of TRPA1 to activate the channel, but this requirement is not shared to the same degree by all TRPA1 agonists (Hinman et al. 2006; Redmond et al. 2014 (365 AE 15%) than in cells expressing the 3xCys-mutant hTRPA1 (85 AE 16%, P < 0.001) (Fig. 4) .
Tetra-o-methyl-NDGA (OMeNDGA, terameprocol) is an analog of NDGA being developed as a chemotherapeutic agent. Terameprocol also produced a concentration-dependent increase in calcium 5 fluorescence in cells expressing hTRPA1, with a pEC 50 of 4.5 AE 0.2 and a maximum change in fluorescence of 550 AE 75% (300 lmol L À1 , Fig. 5 ). The effects of terameprocol (30 lmol L À1 ) were antagonized by preincubation of cells with HC 030031 (Fig. 5 , P < 0.001, n = 6). In C57BL/6 mice intraplantar injection of NDGA and CA at doses of up to 300 and 1000 nmol, respectively, had no effect on spontaneous hind paw movement and produced no overt behavioral effects. At doses of 3000 nmol and above, CA produced whole body responses that were relatively delayed in onset and included decreased locomotion and shaking/shivering.
When acetone was sprayed onto the plantar surface of the hind paw before drug injection, it produced on average of 2.0 AE 0.1 localized hind limb responses (hind paw lifts/flinches/licks) which lasted an average of 7.3 AE 0.3 sec. Intraplantar injection of vehicle did not produce a change in the number of localized hind limb responses to acetone (Fig. 6A and B) . Intraplantar injection of CA produced an increase in the number of localized hind limb responses to acetone which peaked at 15-30 min postinjection and returned to baseline levels within 60 min (Fig. 6A) . The increase hind limb acetone responses produced by intraplantar CA was significantly greater than that produced by intraplantar vehicle at the 100 nmol (P < 0.001 at 15 min), 300 nmol (P < 0.001, 0.01 at 15, 30 min), and 1000 nmol doses (P < 0.0001 at 15, 30 min). The increase in the number of localized hind limb responses displayed dose dependence, with an EC 50 of 60 AE 4 nmol ( Fig. 6A and C) .
Intraplantar injection of NDGA also produced an increase in the number of localized hind limb responses to acetone which peaked at 15-30 min postinjection and gradually returned toward baseline levels (Fig. 6B) . The increase hind limb acetone responses produced by intraplantar NDGA was significantly greater than that following intraplantar vehicle at the 3 nmol (P < 0.0001 at 15 min), 10 nmol (P < 0.0001 at 15 min), 30 nmol (P < 0.0001, 0.01 at 15, 30 min), 100 nmol (P < 0.0001, 0.05 at 15, 30 min), and 300 nmol doses (P < 0.0001, 0.0001, 0.0001, 0.01 at 15, 30, 60 min). The increase in the number of NDGA-induced localized hind limb responses displayed dose dependence, with an EC 50 of 12.0 AE 2.1 nmol ( Fig. 6B and C) . In addition, intraplantar injection of terameprocol (30 nmol) produced an increase in the number of localized hind limb responses to acetone, similar to that observed for NDGA (Fig. 6C) . Finally, we examined the effect of systemic injection of the TRPA1 antagonist HC 030031 on the responses to near maximal doses of intraplantar CA (300 nmol, n = 6) and NDGA (30 nmol, n = 6). Systemic injection of HC 030031 (150 mg kg À1 ) and vehicle did not produce a significant change in the localized hind limb responses to acetone (responses = 0.0 AE 0.3 and 1.1 AE 0.9 for HC 030031 and vehicle, respectively, P = 0.9, 0.2, n = 12, 9). The increase in localized hind limb responses to acetone produced by CA and NDGA were both significantly less in HC 030031 pretreated animals compared to vehicle pretreated animals ( Fig. 6D , P < 0.001).
Discussion
The principle finding of this study is that the unspecific lipoxygenase inhibitor NDGA (Gregus et al. 2013 ) and its 50 and maximum between wild-type and 3xCys-mutant hTRPA1). analog terameprocol are both efficacious agonists at hTRPA1. Consistent with this, both compounds produced enhanced responses to cold stimuli in vivo. These findings suggest that NDGA may not be a suitable probe for lipoxygenase-dependent process in studies of nociception or other responses where sensory nerves modulate tissue activity. They also raise the possibility of a TRPA1-related mechanism contributing to NDGA modulation of cancer cell growth, in addition to the well recognized pathways involving the inhibition of the Sp1 promoter (Hwu et al. 1998; Chang et al. 2004) .
NDGA activation of TRPA1 was not likely to be associated with the inhibition of lipoxygenases because we demonstrated in a concomitant study that application of the lipoxygenase inhibitors caffeic acid and N-oleoyl dopamine to HEK 293-hTRPA1 cells did not activate TRPA1 (Redmond et al. 2014) . The lack of any significant effect of the TRPA1 antagonist HC 030031 alone also indicates that basal activation of pathways producing fatty acid-derived modulators of hTRPA1 is low in HEK 293-hTRPA1 cells, making it unlikely that there is sufficient tone in these pathways for NDGA to shunt substrates to metabolic pathway that produces potent hTRPA1 agonists.
Many reactive molecules such as allyl isothiocyanate (mustard oil), acrolein, iodoacetamide, and CA, activate TRPA1 by binding to or modifying the reactivity of cysteine residues situated on the cytosolic N-terminal domain of the channel (Hinman et al. 2006; Macpherson et al. 2007 ). The apparent capacity of NDGA to activate hTRPA1 was strongly reduced in cells expressing mutant hTRPA1 with Cys621, Cys 641, and Cys665 mutated to serine. These findings are reminiscent of those for nonreactive activators of hTRPA1 such as arachidonic acid, 5-nitro-2-(3-phenylpropylamino) benzoic acid and lidocaine, which show significantly reduced activity at the 3xCys-mutant hTRPA1 (Leffler et al. 2011; Redmond et al. 2014) . This is in contrast to agonists such as CA and allylisothiocyanate, whose activity is essentially abolished by mutation of the N-terminal Cys residues Page 7 (Hinman et al. 2006; Redmond et al. 2014) . Our data further support the role of N-terminal domain cysteines as crucial for receptor function, in addition to their roles as targets for endogenous and environmental electrophiles. The present results indicate that NDGA enhances behavioral responses to cool stimuli and that this is TRPA1 mediated. First, intraplantar injection of NDGA and CA alone had no behavioral effects at room temperature, but increased the behavioral nocifensive responses to evaporative cooling during the local topical application of acetone. This is similar to that previously reported for CA and other TRPA1 agonists (del Camino et al. 2010; Gentry et al. 2010) and is indicative of a specific enhancement of responses to cold stimulation. Some studies have observed that TRPA1 agonists produce behavioral responses at room temperature, however, these observations were made with other agents, or at higher doses of CA than used here (Trevisani et al. 2007; Andrade et al. 2008; Eid et al. 2008; Tsagareli et al. 2010) . NDGA-and CA-induced behavioral effects displayed dose dependence with similar potency and efficacy, consistent with results in vitro. Finally, the behavioral effect of both NDGA and CA were reduced by the TRPA1 antagonist HC 030031, which has previously been shown to inhibit TRPA1-mediated behaviors in vivo (Eid et al. 2008) . The agonist actions of NDGA on a key detector of a subset of noxious sensory information suggests that its usefulness in animal studies of sensory function is limited, as it seems to inhibit the activity of enzymes producing pronociceptive compounds (Gregus et al. 2012 (Gregus et al. , 2013 ), but at the same time be directly activating their potential target. Hitherto unexplained effects of NDGA have been reported in airway smooth muscle (Henry 1994) , a tissue where TRPA1 may be expressed on both neuronal and non-neuronal cells (Caceres et al. 2009; Nassini et al. 2012) .
NDGA and its derivative terameprocol are potential chemotherapeutic agents. Their anti-cancer activity has been demonstrated to arise through to their binding to the Sp1 transcription site on genes involved in regulation of cell cycle progression. These effects of NDGA and terameprocol on cell survival and Sp1-mediated transcription occur at concentrations between 10 and 100 lmol L À1 (Chen et al. 1998; Hwu et al. 1998; CastroGamero et al. 2013) , concentrations that produce a significant activation of TRPA1. By contrast to the inhibitory effects of Sp1 inhibition on cell growth, recent findings indicate that activation of TRPA1 may promote the survival of small cell lung cancer cells (SCLC, Schaefer et al. 2013) , and contribute to a more invasive phenotype in vitro (Du et al. 2014 ). TRPA1 has also been strongly implicated as a mediator of chemotherapy-induced peripheral neuropathy (CIPN, Nassini et al. 2011 ), a major dose-limiting effect of oxaliplatin and cisplatin.
Interestingly, available evidence suggests that unlike NDGA or terameprocol, oxaliplatin and cisplatin activate TRPA1 indirectly via ROS (Nassini et al. 2011) . Given that continuous activation of TRPA1 can lead to profound channel desensitization (Ibarra and Blair 2013; Redmond et al. 2014) , it is an open question whether chronic administration of a TRPA1 agonist like NDGA or terameprocol will lead to exacerbation or inhibition of CIPN or SCLC invasiveness. There is very little information about the systemic administration of terameprocol to humans, however, neuropathic pain was not noted in the most comprehensive report to date (Grossman et al. 2012) . The inhibition of SP1 activity by NDGA and derivatives has also been explored in the context of inhibition of viral replication (Chen et al. 1998; Hwu et al. 1998) , although this has not progressed as far as clinical trials. NDGA also affects a variety of voltage-gated Ca (I Ca , Korn and Horn 1990; Hatton and Peers 1997) and K channels (Hatton and Peers 1997) , as well as the Mg-inhibitable transient receptor potential melastatin-like 7 channel (TRPM7, Chen et al. 2010) , independently of effects on lipoxygenase. The effects on I Ca and TRPM7 are inhibitory and occur over concentration ranges of (5-50 lmol L À1 ).
NDGA effects on K currents (I K ) are more complex, with inhibition of voltage-gated I K contrasting with an efficacious stimulation of large-conductance Ca-activated I K . NDGA activity on these channels may contribute to the chemotherapeutic or other effects of the compound, however, the effects of NDGA on TRPA1 in vitro and cold stimulation in vivo were blocked by an antagonist of TRPA1, indicating a central role for the interaction of NDGA with this channel in the effects we observed. In summary, NDGA and its derivative terameprocol are ligands with a similar efficacy and affinity for the human TRPA1 receptor in vitro. As would be expected from a TRPA1 ligand, local administration of NDGA caused enhanced behavioral responses to noxious cold stimuli. The identification of TRPA1 as another potential site of action for NDGA and its derivatives raises interesting possibilities about new therapeutic mechanisms of action as well as potential adverse effects of this class of compounds. trophysiology, C. W. V and V. M. did the behavioral work. W. J. R. and M. C. Sr. wrote the paper.
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